US issues executive order for AI regulation in healthcare
US president Joe Biden has signed a new executive order laying down a need for a new set of guidelines to better regulate AI as it continues to expand across the healthcare industry.
31 October 2023
31 October 2023
US president Joe Biden has signed a new executive order laying down a need for a new set of guidelines to better regulate AI as it continues to expand across the healthcare industry.
The integrated system will assist in characterising diseases in babies and children with genetic disorders in acute medical settings.
The deal is expected to close in the fourth quarter of this year if it meets customary closing conditions.
The SiPore21 device is currently being evaluated for managing pre-diabetes in a clinical trial.
The company is offering laboratories a new in-vitro diagnostics solution for the diagnosis of patients with autoimmune diseases.
Sebela Women’s Health has announced that its investigational copper IUD shows a reduction in pain and bleeding in post-hoc analysis.
Maverick qPCR instruments integrate technological advancements developed by Anitoa Systems.
In the trial, 152 patients have been randomised to either the selective laser trabeculoplasty or ViaLase Laser.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
The healthcare, pharma, and medical devices industries are often risk-averse compared to other sectors when adopting new technologies. However, mainly due to COVID-19, these sectors have witnessed an acceleration in digital transformation. AI can revolutionize the drug discovery process and significantly reduce the time and cost to get a drug to market, particularly in areas of unmet need. There is also huge potential for AI in medical diagnostics. However, using healthcare data for AI development raises data privacy concerns, thereby limiting its adoption.
Give your business an edge with our leading industry insights.